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CAR T-Cell Therapy: A New Road to Treat Cancer 
Kyle Gilkeson 
Abstract 
Accounts of cancer have been around for many centuries. The ‘War on Cancer’ has officially 
been going on since 1971 with the passing of the National Cancer Act. The aim of this was to 
understand more about the behavior and biology of cancer in addition to the development of 
efficacious drug therapies. Although such therapies have been discovered and developed, the 
precision of ‘traditional chemotherapeutics’ have shown not to be as precise as desired. For 
example, these drugs aim to kill cancer cells that are dividing at a higher rate than normal 
relative noncancerous cells. However, noncancerous cells that require to divide rapidly (gut, 
epidermis, keratinocytes of the scalp) are prone to these traditional chemotherapies and as such 
patients experience undesirable side effects. The aim of this paper is to address the development 
of a novel cellular-based cancer therapy called CAR T-cell therapy. The structure of such a 
therapy enables greater precision than traditional chemotherapies and potentially greater efficacy 
than standard cancer immunotherapy drugs. The structure, function, and cytotoxic mechanisms 
of CAR T-cells will be addressed along with landmark clinical trials that have lead to the US 
FDA approval of two CAR T-cell therapies. In addition to successes, consequences of this 
therapy will be discussed involving toxicities, economic costs, and hardships against solid 
tumors. 
Keywords: CAR T-cell, cytotoxic mechanisms, CAR T-cell generations, CAR T-cell structure 




Cancer has been noted since the ancient Egyptian times. The word ‘cancer’ comes from the Latin 
word ‘crab.’ More so, the crab is the zodiac sign of Cancer. Cancer is one of the most 
devastating and debilitating diseases in the modern era. Millions are diagnosed in the United 
States each year and it is the second most common cause of death behind heart disease. With 
such a devastating impact to those diagnosed and to their loved ones, relentless hours of research 
and funding have been spent to try and elucidate what cancer is, what causes cancer, what risk 
factors there are, how it can be most effectively treated, and finally how it can be cured. 
Throughout the years, it has been found that there are several risk factors that contribute to the 
development of cancer. These include, but are not limited to, tobacco smoking, excessive alcohol 
consumption, infectious diseases (Human Papilloma Virus, Hepatitis C, Hepatitis B), excessive 
sun exposure and/or tanning bed use, and physical inactivity.[1] 
It’s widely known and agreed upon that cancer is the result of an accumulation of several 
mutations that induce cell division to become unregulated. Therefore, traditional 
chemotherapeutic agents have aimed to exploit such cell cycle metabolic pathways of cancer 
cells to impede their aberrant division. Some of these drugs unfortunately do not have the ability 
to differentiate between a cancerous cell and a normal cell. For example, due to the fact cancer 
cells rapidly divide, traditional chemotherapeutic drugs work to target such rapidly dividing 
cells. Unfortunately, there are other tissues that can be healthy and divide rapidly such as 
gastrointestinal cells of the intestines, epidermal cells of the skin, and keratinocytes of the scalp. 
Due to this commonality, traditional chemotherapeutic drugs cause unfavorable side effects at 
the sights of these normal, healthy, rapidly dividing cells. Fore example, some side effects could 
include hair loss, diarrhea, and even fragility of the skin to name a few. Due to such undesirable 
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side effects, cancer researchers have sought to develop chemotherapeutics that are even more 
precise to target cancer cells vs. noncancerous cells. 
Fortunately, there are some chemotherapeutic drugs on the market that do have the ability to 
target cancer cells more precisely. This is dependent upon the type of cancer the patient has been 
diagnosed with as well as the specific receptors those cancerous cells express. The cancerous 
cells may express a unique receptor that a normal cell does not, or the cancerous cells may 
express a certain receptor in a higher ratio compared to normal cells. Although targeted 
chemotherapy provides a better means to differentiate cancerous from noncancerous cells, it is 
not perfect and still comes with harsh side effects like traditional chemotherapy can cause. 
Traditional and targeted chemotherapeutic drug regimens have had their successes in many 
cancer patients but also have experienced failure in others. Again, there are a multitude of factors 
that play a role in the success of a chemotherapy regimen. For example, the type of cancer can 
give insight into how aggressive it is and therefore the prognosis. More so, the staging of the 
cancer at the time of diagnosis plays a crucial role into the success of treatment. Unfortunately, 
cancer can have the ability to become resistant to the chemotherapy given to the patient by way 
of upregulating drug efflux ABC transporters or by downregulating the expression of those 
proteins/receptors being targeted by the chemotherapy drugs, to name a few ways. Also used in 
conjunction with chemotherapy is radiation therapy and surgical excision. Advances in 
technology and research have allowed radiation therapy to provide a precise and specific route to 
treat the cancer. These other two forms of treatment can have their limits as well. Radiation 
therapy may not be ideally suited for those cancers that have spread considerably in the GI tract. 
In addition, surgical excision may not always provide a safe and operable way to reach a tumor 
for excision. It should be stated that no therapy or drug is perfect and always has a benefit-to-risk 
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ratio. Cancer treatment has advanced considerably through the years to prolong and even save 
the lives of those diagnosed with it. 
Sometimes the best medicine is preventative medicine. As such, quality nutrition plays a 
significant role in the smooth, normal functioning of the human body. An important and vital 
system that sustains the well-being of the human body is the immune system. The immune 
system is comprised of diverse, vital cells combating not only foreign pathogens but also cancer. 
It is logical to deduce from this that cancer develops largely in part due to the immune system 
being defective in some manner. Therefore, cancer immunotherapy has been a hot area of 
research for many years. The well-known cells involved in detecting and destroying cancer cells 
directly are the CD8+ cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, dendritic cells, 
and macrophages. Of course, this list is by no means exhaustive. However, it has been an 
intensive goal to exploit the cytotoxic effects of these cells and stimulate or manipulate them to 
target cancer cells directly. 
CAR T-Cell Overview 
Fortunately, there has been recent advances and findings for a novel therapeutic approach to treat 
cancer, with the most promising patient outcomes being those diagnosed with nonsolid cancers 
such as lymphomas and leukemias. This therapy is unique in that it is not a drug but rather a 
genetic manipulation and engineering of the T-cells of a patient’s immune system to precisely 
recognize and differentiate cancer cells from healthy cells. The T-cells are collected from the 
patient’s blood and then separated from red blood cells and other components via leukophoresis. 
This novel, nondrug, cellular therapy is known as chimeric antigen receptor (CAR) T-Cell 
therapy. The term ‘chimeric’ derives from ‘chimera’ meaning mixture or combination. Thus, 
CAR implies the T-cell has been genetically altered to express a combinatory structure of an 
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antibody, a transmembrane domain, and the constant regions of a T-cell receptor (TCR) for the 
intracellular domain. The extracellular domain of a CAR consists of a single chain variable 
fragment (scFv). The scFv is connected to the transmembrane domain by a hinge domain. This 
scFv mimics the variable region of a typical antibody which can bind a specific epitope it 
recognizes. These scFv domains of a CAR are therefore engineered to be specific for a protein 
that is expressed by a cancer cell. Theoretically, the manipulation of scFvs can provide a highly 
specific means to target many different cancer types. Upon scFv binding a cancer cell antigen, 
the signal is transmitted to the intracellular domain of the CAR resulting in T-cell activation. The 
CAR confers a couple advantages due to its structure. First, the extracellular scFv domain 
provides direct specificity against cancer cells expressing antigens and enables the bypassing of 
antigen presentation via Major Histocompatibility Complex (MHC) to stimulate and activate T-
cells. However, there is a disadvantage to the specificity the scFv domain confers. Not all 
cancers express a unique antigen that healthy cells do not. Some antigens expressed by tumors 
can be shared between healthy and cancerous cells. More optimistically, some antigens may be 
overexpressed in greater density in cancerous cells vs. healthy cells thereby favoring the 
eradication of cancerous cells relative to normal cells.  
CAR T-Cell Structure, Function, and Evolution 
The development of CAR T-cells has been an extensive process that has yielded promising 
outcomes in some clinical trials. There has been development of several generations of CAR T-
cells that have been both researched intensively and/or tested clinically. The first CAR T-cells 
developed were known as first generation CAR T-cells. These consisted of an scFv extracellular 
domain attached to a hinge domain. This hinge domain is the link between the transmembrane 
domain and the scFv domain. The unique feature of the first-generation CAR T-cells is the 
6 
 
identity of the intracellular domain which is linked to the transmembrane domain as described 
above. The first-generation CAR T-cell consisted of the cluster of differentiation-3 zeta (CD3ζ). 
In normal T-cell activation, the TCR needs to bind to an antigen presented on MHCI or MHCII 
(dependent upon whether the T-cell is CD4+ or CD8+). Once bound, there needs to be cross-
linking of TCRs to optimally activate the intracellular signaling cascade within the T-cell. The 
CD3ζ is an accessory costimulatory molecule associated with the TCR and upon TCR binding to 
a presented antigen on MHC, the cytoplasmic domain of CD3ζ becomes activated. The 
cytoplasmic domain of CD3ζ contains what are known as immunoreceptor tyrosine-based 
activation motifs (ITAMS). These motifs are tyrosine rich and will be phosphorylated by a 
protein called Lck. The subsequent phosphorylated tyrosines will become sites of docking for 
adaptor proteins as well as another well-known protein named zeta-associated protein of 70kD 
(ZAP-70). Ultimately two signal transduction pathways will ensue upon TCR binding to a 
presented antigen. One pathway is the Ras/Rac-MapK pathway and the other is the Ca2+-NFAT 
pathway. The latter pathway results in the activation of the transcription factor NFAT which will 
stimulate the expression of IL-2 and its respective receptor (IL2-R). IL-2 is known as the T-cell 
growth factor. The former pathway will result in the activation of the transcription factor 
activating protein-1 (AP-1) which will also stimulate the expression of T-cell activating genes. 
Given the overview of normal TCR activation, it can be seen that CD3ζ is an important 
component of the cytoplasmic domain of a CAR T-cell helping with activation, persistence, and 
proliferation. However, it has been found in early clinical trials[3] as well as in other studies that 
the use of CD3ζ alone is not sufficient to induce CAR T-cell persistence and proliferation.[2] 
With the additional integration of another costimulatory molecule, CD28 or 4-1BB, comes a 
more robust proliferation and persistence of CAR T-cells. With this came the development of 
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what are called second generation CAR T-cells. The main difference between the second 
generation and the first is that the second generation has an additional costimulatory endodomain 
in the CAR (two total). CD28 and 4-1BB intracellular domains are what have been used in 
clinical trials and have shown promising results against hematological malignancies. When 
positive clinical results were observed using second generation CAR T-cells, further 
modification of CARs were engineered to consist of at least three or more total costimulatory 
endodomains. It is worth noting that these additional costimulatory molecules are linked in 
tandem with the CD3ζ domain. These became known as third generation CARs, fourth 
generation CARs, and so on. The additional costimulatory domains that have been added and 
have shown enhanced CAR T-cell proliferation, persistence, and activity are CD28, 4-1BB, 
OX40, CD27, and inducible T-cell co-stimulator (ICOS or CD278). As reported by Guedan et 
al., a third generation CAR T-cell with the intracellular domains CD3ζ, 4-1BB, and ICOS 
showed greater persistence and lethality towards tumors given that the ICOS domain is proximal 
to the transmembrane domain of the CAR.[4] It was shown from this same study that ICOS 
mediates the phosphoinositide-3 kinase (PI3K) signaling pathway resulting in increased 
expression of Akt. The endodomain ICOS plays a critical role in signal transduction in that it 
provides a docking site for PI3K signaling activation. An important well-known T-cell survival 
factor protein is Akt which can help with the persistence of T-cells to target cancer cells. Other 
exciting findings have been found via the use of ICOS as a costimulatory molecule in second 
generation CAR T-cells in mice against a human infused tumor. A study was conducted by 
Paulos et al. and was reported that the use of CAR T-cells with ICOS-CD3ζ costimulatory 
intracellular domains, upon stimulation of the CAR T-cells, resulted in the differentiation, 
persistence, and antitumor activity of T-helper 17 cells (TH17) compared to CAR constructs with 
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CD28- CD3ζ intracellular domains.[7] Additionally, findings from this study reported ICOS 
stimulation induced secretion of IL-21, IL-17, and IFN-γ. These secreted cytokines pose 
antitumor effects and boost the activity and persistence of CAR T-cell activity.  
Fourth Generation CARs (TRUCKS) 
Fourth generation CAR T-cells are a unique design maintaining the standard structure of the 
CAR but also contain the ability to release a transgenic protein upon CAR T-cell activation. This 
generation of CAR T-cells are also known as ‘T-cells redirected for universal cytokine-mediated 
killing’ (TRUCK). As the name implies, the transgenic protein is a cytokine that can be induced 
or released in a constant manner into the extracellular space which will then carry out antitumor 
effects. Commonly tested cytokines used thus far have been IL-12 and IL-18. It has been 
reported that the use of IL-12 secreting TRUCKs resulted in significant antitumor activity as well 
as even suppression of the tumor microenvironment and suppression of Treg cells.
[5] In addition, 
IL-18 secreting CAR T-cells (TRUCKs) showed similar results to IL-12 secreting CAR T-cells. 
It was found by Hu et al. that such IL-18 secreting CAR T-cells showed significant proliferation 
and antitumor activity.[6] The further innovation and refining of CAR T-cells provides a more 
potent way to attack cancer cells. It will be interesting to see future results from clinical trials in 
utilizing TRUCKs to combat cancer. 
More Diverse CAR Constructs: 5th Generation/Next-Generation CAR T-cells 
Even though second-generation CAR T-cells have shown promising results in clinical trials 
against hematological malignancies, they are by no means one hundred percent effective. 
Furthermore, more success is trying to be replicated against solid tumors such as pancreatic, 
liver, colon cancer, etc. Nor do they convey toxicity free side effects from the therapy. Therefore, 
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even more intensive research has continued into the development and design of CAR constructs 
that can more effectively and precisely target the tumor and not healthy tissue as well as to 
reduce toxicity as much as possible. So far there have been successes on such developments and 
designs and several of them will be mentioned and include: Pooled CAR T-cell, Multi-CAR T-
cell, Tandem CAR T-cell, Conditional CAR T-cell, iCARs, and Suicide Switch CAR T-cells. 
Pooled CAR T-cells are comprised of at least two or more CAR units each consisting of their 
own unique scFV domain expressed in different populations of CAR T-cells. More simply put, 
there are multiple CAR T-cells each expressing a unique CAR against a tumor antigen. Multi-
CAR T-cells contain multiple unique CARs, each recognizing their tumor antigen via their scFv 
domains. As can be deduced from this construct, this can enhance the precision for targeting 
tumor cells rather than healthy cells which is known as ‘on-target on-tumor’ activity. The 
Tandem CAR T-cell has multiple, usually two, unique scFv domains linked together. 
Conditional CAR T-cells consist of two separated CAR constructs. One construct consists of the 
activation domain (CD3ζ) and the other consists of a costimulatory domain (CD28, 4-1BB, 
OX40 or ICOS, etc.). Each construct contains a unique scFv domain recognizing different tumor 
antigens. iCARs have been genetically manipulated to express a receptor. Once the respective 
ligand binds to this receptor, it will induce an inhibitory signal in the CAR T-cell. The ligand that 
binds this receptor is expressed by healthy tissue and therefore provides a ‘safety’ mechanism to 
prevent cytolytic activity against healthy cells. In a similarly related concept, suicide switch 
CAR T-cells can also be engineered to contain a suicide switch/gene, usually Caspase-9, that can 
be activated to abort the cytotoxicity of CAR T-cells via apoptosis.  
Cytotoxic CAR T-cell Killing Mechanisms 
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The normal cytotoxicity of T-cells are exploited and phenotypically consistent with the killing 
action of CAR T-cells. There are several different pathways, working together, to induce cell 
death of cancer cells. The pathways that will be touched upon include: Perforin/Granzyme (P/G) 
release, Fas/Fas-Ligand interaction, and the release of cytokines into the interstitial space. The 
P/G release pathway involves the regulated exocytosis of cytotoxic granules into the extracellular 
medium which will act on the tumor cell’s plasma membrane. The lytic enzymes released will 
perforate the cell membrane allowing the entry of granzymes. These granzymes promote 
activation of caspase enzymes in the tumor cell and subsequent induction of both caspase 
dependent and independent pathways.[8] The second pathway by which CAR T-cells mediate 
antitumor activity is the Fas/Fas Ligand pathway. CAR T-cells, upon activation, will upregulate 
the expression of Fas-Ligand at the cell surface increasing the probability of binding to the Fas 
receptor on the cancer cell. Once this pathway is activated, it will stimulate downstream 
signaling events leading to the formation of death-inducing signaling complex (DISC) and 
subsequent activation of capsase-3 leading to apoptosis of the tumor cell. Cytokine release 
directed by CAR T-cells was described above in ‘Fourth Generation CARS (TRUCKs).’ It may 
be worthy to note that cytokines of interest being studied involve not only the prior mentioned 
IL-12 and IL-18, but also the release of IFN-γ. IFN-γ is a well-known antitumor cytokine, 
surveilling the presence of cancer. However, it has been discovered in several studies that IFN-γ 
receptor is downregulated by cancer cells, a phenomenon known as tumor evasion owing to 
therapy resistance by tumors.         
Hardships Against Solid Tumors 
Much of the clinical success using CAR T-cell therapy has been against hematological 
malignancies, such as B-cell lymphomas and leukemias. Several factors are at play contributing 
11 
 
to such success and include the ease of the CAR T-cells traveling throughout the body to reach 
the tumor sites, a highly specific tumor antigen that is expressed by many hematological 
malignancies (CD19 and CD20), as well as less of a struggle engaging against the stroma of the 
tumor microenvironment. CD19 is an ideal tumor antigen to target because it is ubiquitously 
expressed by normal B-cells throughout all the stages of differentiation from the pro-B cell stage 
onward as well as on those B-cell malignancies. It is also expressed by follicular dendritic cells 
but is not expressed by other tissues or hematopoietic stem cells.[8] This helps to ensure more 
precise targeting by anti-CD19+ CAR T-cells and thus reduce toxicity at other tissues. 
Furthermore, since CD19 is expressed on both healthy B-cells and cancerous B-cells, CAR T-
cells will work to eliminate both resulting in what is called aplasia of healthy B-cells. 
Fortunately, this outcome can be easily managed via immunoglobulin replacement therapy. This 
entails the delivery of mainly IgG into the treated patient. Delivery can be by way of intravenous 
or subcutaneous routes. Unfortunately, many solid tumors such as liver cancer, pancreatic 
cancer, and colon cancer do not express unique tumor antigens like that seen in the B-cell 
malignancies. Thus, it’s critical to identify tumor antigens of such cancers that express it at 
higher numbers relative to normal tissue as well as that tumor antigen ideally needs to be 
expressed in a local fashion rather than a systemic fashion. For example, CAR T-cells were 
designed to target ERBB2 in a patient with breast cancer. Unfortunately, the patient experienced 
a severe adverse event during the course of her treatment and died. It was later found that 
ERBB2 is widely expressed not only by breast tissue of the cancer cells but also on normal tissue 
of the lungs.[9]  
In addition to solid tumors not expressing unique antigens associated with the tumor, CAR T-
cells have more of a difficult time traveling to and infiltrating the tumor. The CAR T-cells have 
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to traverse the circulatory system and exit at the location of the tumor. In addition, once at the 
tumor location, the CAR T-cells have to overcome and penetrate a hostile environment known as 
the tumor microenvironment. This tumor microenvironment contains immunosuppressive 
cytokines, immunosuppressive cells (Tregs and TH17 cells), the extracellular matrix, and other 
cells consisting of the tumor stroma. Methodologies on how to administer CAR T-cells to 
combat solid tumors are being tested or have been previously tested. Such methodologies 
involved the delivery of the CAR T-cells into the region of where the tumor is located as 
opposed to the intravenous administration of CAR T-cells. A benefit to local delivery involves 
using less total counts of CAR T-cells to mount an antitumor response and thus poses less of a 
threat to toxic effects for the patient.  As stated previously, tumors secrete a host of biological 
molecules that induce immunosuppression of CAR T-cells. Some of these molecules that will be 
discussed include TGF-β, IL-4, IL-10, PGE2, and sialomucins. In addition, tumors induce the 
recruitment of T regulatory cells, TH17 cells, myeloid-derived suppressor cells (MDSCs), and 
cancer associated fibroblasts (CAFs). 
TGF-β is a well know soluble inhibitor of T-cell activation. TGF-β are one of the many soluble 
cytokines responsible for the failed persistence and cytotoxicity of CAR T-cell therapy. It has 
been reported in a study that TGF-β binds its receptor on the T-cell in a mouse model and acts to 
induce the suppression of genes that express proteins pertinent to a T-cell’s cytotoxicity. These 
proteins include: Perforin, Granzyme A (GzmA), GzmB, IFN-γ, and FasL[10]. Interestingly, from 
this same study, it was found that once the TGF-β was removed, the T-cells regained their ability 
to attack tumor cells.  
IL-10 is another immunosuppressive cytokine contributing to decreased efficacy of CAR T-cell 
therapy. It has been shown to induce downregulation of TAP 1/2 which is involved in the 
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processing of antigen presentation onto MHC. Therefore, this cytokine negatively impacts the 
functionality of antigen presentation by professional antigen presenting cells like dendritic cells 
and macrophages. PGE2 was reported to be manufactured at high levels by an overexpressed 
COX-2 enzyme in a human derived glioma cell line. This resulted in the stimulation of mature 
dendritic cells to secrete IL-10. This resulted in the mature dendritic cells to induce CD4+ T cells 
to adopt a Treg1 phenotype characterized by the secretion of IL-10 and TGF-β, potent inhibitors 
of T-cell cytotoxicity.[11] 
Sialomucins, specifically Muc1, are overexpressed in many solid tumors like breast and colon 
cancers. In a study conducted by Agrawal et al., tumor secreted Muc1 was found to impede T-
cell proliferation. Interestingly though, this inhibited proliferation could be reversed by addition 
of IL-2 as well as administration of anti-CD28 monoclonal antibody.[12] CAFs are abundantly 
present in the stroma of the tumor microenvironment and express the surface protein fibroblast 
activation protein (FAP). To increase the efficacy of CAR T-cells against solid tumors would be 
to engineer separate pools of CAR T-cells. One pool to target against the FAP expressed on 
CAFs and the other pool to target against a tumor specific antigen. Another highly expressed 
tumor antigen expressed is vascular endothelial growth factor-2 (VEGF-2) which helps enable an 
increased vascular supply for the tumor to support rapid growth and subsequently possible 
metastasis. Therefore, the development of CAR T-cells to target against VEGF-2, CAFs, and the 
tumor associated antigen can increase the potency against the tumor and its associated 
microenvironment. Dendritic cells are a vital type of antigen presenting cells that play a pivotal 
role in tumor immunosurveillance. The tumor contributes to a microenvironment that impedes 
the maturation of dendritic cells. The tumor is also capable of upregulating the expression of 
FAS-L and PD-L1 at the tumor plasma membrane to suppress immune cells. Cancer cells induce 
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a high lactate and low tryptophan type of microenvironment that induces immunosuppression. 
CTLA-4 is expressed at the membrane of activated T-cells and engagement with CD80 and 
CD86 with antigen presenting cells induces an inhibitory signal to the T-cells. 
Enhancing the cytotoxicity and persistence of CAR T-cells against solid tumors would seem to 
require additional immunotherapy medicines. Next generation CAR constructs could be utilized 
to combat both the immunosuppressive tumor microenvironment and the tumor itself. Separate 
pools of CAR T-cells could effectively combat solid tumors. CAR T-cell Pool A could be 
engineered to target a tumor specific antigen and Pool B could be targeted against those soluble 
immunosuppressive cytokines. Binding of such a CAR (expressed by Pool B) to an 
immunosuppressive cytokine can turn a normally biologically inhibitory signal into a stimulatory 
signal causing the CAR T-cells to become active. In addition, monoclonal antibodies could be 
used adjunctively to inhibit immunosuppressive cytokines and/or inhibit the activation of those 
cytokines’ respective receptors.  
Solid Tumor Trials 
According to Schmidts et al., there are well over 80 clinical trials testing CAR T-cells against 
solid cancers as of 2017.[13] The cancers that are being targeted against include neuroblastoma, 
glioblastoma, epithelial cancers, hepatic cancer, and prostate cancer. In 2011, a study was carried 
out using CAR T-cells directed against GD2+ neuroblastoma cells. Although the results from this 
study were not as successful as therapies against hematological malignancies, promising results 
were recorded and insights were learned. Three of the eleven patients treated who had active 
disease experienced complete remission[14] and an average long term persistence of the CAR T-
cells for over 40 weeks. A study has been completed involving the use of CAR T-cells against 
EphA2 gliomas (NCT02575261). However, no results have been posted yet. With time, it will be 
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interesting to see the development and use of newly designed CAR T-cells against solid tumors 
and the use of adjunct immunotherapy to help maximize efficacy against solid malignancies. 
Landmark Hematological Malignancy Trials 
There have been a few landmark clinical trials reporting exciting results concerning the efficacy 
of CAR T-cell therapy against hematological malignancies. These trials include the ELIANA 
trial, ZUMA-1 trial, JULIET trial, and the TRANSCEND trial. The phase 2 ELIANA clinical 
trial provided successful results and ultimately led the U.S. Food and Drug Administration to 
approve tisagenlecleucel-T. This therapy will be elaborated on in the next section but will be 
noted here that it is used to treat B-cell acute lymphoblastic leukemia. ELIANA results reported 
an 81% overall response rate (ORR) and a 60% complete remission (CR) rate. More to this is the 
80% 6-month relapse-free survival (RFS) rate that was noted.[17] This trial contained 75 children 
and young adults. The toxicities of this study were frequent with 73% of the patients 
experiencing severe adverse events (grade 3 or higher) and 47% developing severe CRS. To 
note, a severe adverse event that is grade 3 is severe and/or medically significant but is not 
immediately life-threatening. Grade 4 indicates life-threatening signs/symptoms requiring 
immediate medical attention and grade 5 indicates death related to the severe adverse event. 
The phase 2 ZUMA-1 trial results reported led to the U.S. FDA to approve a second CAR T-cell 
therapy, axicabtagene ciloleucel. This is used to treat aggressive lymphomas that are refractive. 
More specifics of this therapy are described in the next section. Data from this trial came from a 
patient sample size of 101. There was an 83% ORR along with a 58% CR rate. With a follow-up 
of nearly 27 months, 39% had ongoing responses. Relative to tisagenlecleucel therapy, a higher 
incidence of severe neurotoxicity was reported at 32%. However, a less reported incidence of 
CRS was reported at 11%.[17] 
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The JULIET trial assessed a therapy that was later approved by the FDA to treat relapsed and 
refractory lymphoma. Of the 93 patients treated who had been diagnosed with diffuse large B-
cell lymphoma (DLBCL), 40% showed a CR. Of all those cases a duration of 29.3 months was 
reported upon follow-up. Neurotoxicity was reported at 12% (grade 3 or higher) and CRS at 22% 
(grade 3 or higher).[17] 
The TRANSCEND trial is looking at a potential therapy that could be approved by the FDA in 
the future. The therapeutic product, meant to treat DLBCL, is called lisocabtagene maraleucel 
and showed promising results in the TRANSCEND trial. An 80% ORR, 55% CR rate has been 
reported. Furthermore, 50% continued to be in remission at 6 months. What is interesting to note 
is the low rate of severe adverse events that have been reported. Just one patient had CRS (grade 
3 or higher) and neurotoxicity was reported at 12% (grade 3 and 4).[17] From these exciting 
results, a clinical trial is continuing to be studied and is expected to be complete in August, 2022 
(NCT03744676). 
 
Current FDA-Approved Treatments Against Hematological Malignancies 
In 2017 the U.S. Food and Drug Administration (FDA) approved the use of two unique designs 
of CAR T-cells to treat hematological malignancies due to prior clinical trial successes.  The 
therapies approved are named Kymriah® and Yescarta®. Tisagenlecleucel (Kymriah®) is meant to 
treat pediatric patients who are younger than 25 years-old and have B-cell precursor acute 
lymphoblastic leukemia (ALL) that is either refractory or in a second or later relapse. In addition, 
it can treat adult patients with R/R large B-cell lymphoma after two or more lines of systemic 
therapy including diffuse large B-cell lymphoma (DLBCL) not specified otherwise and high 
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grade B-cell lymphoma and DLBCL arising from follicular lymphoma.[15] Axicabtagene 
ciloleucel (Yescarta®) is meant to treat adult patients with relapsed/refractory large B-cell 
lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma 
(DLBCL) not specified otherwise, primary mediastinal large B-cell lymphoma, high grade B-cell 
lymphoma, and DLBCL arising from follicular lymphoma[16].   
The structure of Kymriah® CAR T-cells follows a second-generation construct. The scFV region 
of the CAR is targeted against the tumor associated antigen CD19. The intracellular domains 
consist of 4-1BB and CD3ζ. As stated earlier, the CD3ζ is responsible for T-cell activation and 
cytolytic toxicity towards its target cell. 4-1BB is responsible for T-cell proliferation and 
persistence. Yescarta® CAR T-cells also follow a second-generation construct. The intracellular 
domains also consist of CD3ζ but differ in the identity of the second intracellular domain which 
is CD28.  
Toxicities 
Provided that there has been promise in the use of cellular based cancer therapy, there has been 
some noted toxicities associated with the administration of such therapy. The two main toxicities 
that have been noted are known as cytokine release syndrome (CRS) and immune effector-cell 
associated neurotoxicity syndrome (ICANS) or just generally termed neurotoxicity. Some other 
toxicities that have been observed has been touched in this report earlier relating to on-target off-
tumor toxicity. This is seen when the CAR T-cell recognizes the tumor associated antigen it is 
directed against but unfortunately it is at other tissue locations also expressing such an antigen. 
CRS culminates due to the large number of CAR T-cells becoming activated once engaged with 
their cancer cell target. This on-target engagement results in the release of cytokines with the 
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concentrations of those cytokines determining the severity of toxicity. As in an immune response 
to a mild cold or flu, the release of cytokines in CRS can induce mild symptoms like fever, 
fatigue, joint pain, etc. However, there has been severe adverse reactions because of CRS. These 
symptoms follow what is seen in a severe immunological reaction to foreign pathogens. In high 
enough concentrations, cytokines can induce circulatory shock and multi-organ system failure 
which is lethal to the patient. Fortunately, the symptoms of CRS can be reversible by 
administering the patient with drugs that act to antagonize proinflammatory cytokines such as 
IL-6. Administering drugs that block IL-6 receptors or IL-6 itself has shown to quickly reverse 
the symptoms of CRS. There has been no elucidation yet on the mechanisms that induce ICANS. 
Symptoms of ICANS include confusion, cerebral edema, and seizures to name a few. It has been 
observed that ICANS can occur with CRS but no clear direct association has been proven yet. 
Given the potential toxic severity that can be experienced by patients infused with CAR T-cells, 
there is interventional treatment that can be administered to save the patient’s life. Treatment 
involves the use of drugs that antagonize proinflammatory cytokines (IL-1, IL-6, etc.) and their 
respective receptors. In addition, glucocorticoids can also be used to treat toxic symptoms given 
that they are potent anti-inflammatory compounds. 
Economic Costs of CAR T-cell Therapy 
The concept of utilizing CAR T-cells to specifically attack tumors has shown promising results 
against hematological malignancies. The ability to translate these promising results against solid 
tumors has shown to be difficult with less success than against hematological malignancies. 
Compounding this drawback against solid malignancies is the economic burden this treatment 
imposes on those patients receiving this form of cellular based treatment. Unfortunately, the cost 
for each patient to be treated with Yescarta® CAR T-cell therapy is $373,000 and $475,000 to be 
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treated with Kymriah®.[18] An important note to add to this is that these dollar amounts do not 
include hospital costs, doctor visits, or additional immunotherapy that may be administered to 
treat CRS, for example. Table 1 (below) is a representation of the expensive costs that go into the 
treatment of pancreatic cancer. The cohort under study included men ≥66 years-old and the costs 
seen come from Medicare payments. As can be deduced from this information is that accrued 
costs incurred on patients treated by FDA approved CAR T-cell therapy can surmount to well 
over $500,000. This could most likely be even more expensive if one considers those cancer 
patients who are years younger and therefore are likely to experience more visits to the hospital 
or their physician’s office for check-ups.  
Conclusions and Future Directions 
Chimeric antigen receptor (CAR) T-cells represent a cellular based cancer therapy generated by 
genetically engineering a receptor and getting it to be expressed by a cancer patient’s own T-
cells. This is done by collecting a sample of blood from the patient and isolating their T-cells, a 
process called leukophoresis. Delivery of the CAR is usually done by way of retroviral or 
lentiviral vectors. It should be noted that this is not the only way of delivering the CAR gene. For 
example, delivery can be done via injection of a plasmid. The CAR construct can be manipulated 
to recognize and bind to TSAs. It especially important to target a TSA that is uniquely expressed 
by a tumor cell or is expressed in a more relative abundance compared to normal healthy cells. 
This helps to maximize the safety of this cell-based therapy by limiting ‘on-target/off-tumor’ 
effects and thus toxicity to the recipient. The most success of CAR T-cell therapy has been 
against hematological malignancies. This is due to these types of cancers being ‘soluble’ and 
thus the delivery of this therapy is efficacious compared to solid tumors. Further, some 
lymphomas and leukemias express TSAs (CD19 and CD20) that are not expressed at other tissue 
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sites. Treatment against solid tumors has proven difficult due to a suppressive TME consisting of 
both immunosuppressant cells (CAFs, Th17) and immunosuppressant cytokines (IL-4, IL-10). 
However, refining the development and further experimentation with next-generation CAR T-
cells could provide promising solutions to treat solid tumors in the future.  Other downfalls of 
CAR T-cell therapy include the CRS and neurotoxicity as well as the expensive costs to 
manufacture CAR T-cells. The toxicity of this therapy can be managed appropriately with 
closely monitoring the recipient throughout the treatment and administering the appropriate 
medication to negative toxic levels of cytokines in the body. Despite the downfalls, CAR T-cell 
therapy is revolutionizing a way to treat cancer. It has shown to be efficacious against 
hematological malignancies leading to the US FDA to approve two types of therapies. With 

















Figure 1 represents the general structure of a CAR. The CAR with four domains (rectangles) 
represents the first-generation CAR. The light gray domains represent the scFV domains. The 
charcoal color domains represent the transmembrane domain. The blue domains represent CD3ζ. 
The white domain signifies the structure of a second-generation CAR. This can consist of either 
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